Available Technologies

Browse Penn-owned technologies available for licensing.

One-step synthesis of cationic steroids for gene delivery, anti-inflammatory activity, and antimicrobial activity.

Reagents for improved DNA lipofection, depot anti-inflammation, and/or topical antimicrobial therapy

Technology Overview: 

Researchers in the Diamond Lab have developed a versatile new class of pharmacologically-active molecules with multiple applications. These molecules deliver plasmids (pDNA), adenovirus (AdV), and adeno-associated virus (AAV) to cultured cells and to pulmonary epithelium in vivo.  In addition to their gene delivery capabilities, the structure of the molecules allows them to function as slow-release prodrugs for local treatment of vector-associated inflammation. Importantly, this therapeutic effect may synergize with the gene that is delivered. 

The anti-inflammatory effect of the cationic steroids does not require DNA, and as the prodrugs degrade, they break down into non-toxic materials with pharmacological activity. The molecules can be readily synthesized in one-step from inexpensive precursors in a scalable reaction and purified in gram quantities. Additionally, the cationic steroids have potent antimicrobial activity against gram-positive and gram-negative bacteria, including clinical strains of MRSA and pseudomonas.


  • Efficient delivery of genes to cultured cells
  • Synergistic combination of gene delivery and anti-inflammatory effects to enhance gene therapy
  • Rapid production of compound in large quantities
  • Potent and rapid bactericidal activity against drug-resistant bacteria


  • Gene therapy via non-viral gene delivery
  • Slow-release therapeutics for treatment of inflammation
  • Enhancer of DNA vaccines
  • Pulmonary infections


Synthesis of a cationic steroid for gene delivery and anti-inflammatory activity. From Gruneich et al, 2004.

Stage of Development: 

Proof-of-concept and mouse in vivo data

Intellectual Property: 

Reference Media: 

Desired Partnerships: 

  • License
  • Co-development

Patent Information:


Docket # N2612

For Information, Contact:

Joshua Jeanson Associate Director, SEAS/SAS Licensing Group
University of Pennsylvania